Revenue
No reported data
SpyGlass Pharma, Inc. (SGP)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2023
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Research & development | $29.2M | $20.0M |
| Operating expenses | $41.4M | $27.1M |
| Operating income | −$41.4M | −$27.1M |
| Net income | −$39.9M | −$29.2M |
| Basic EPSper diluted share | -$17.98 | -$16.31 |
| Diluted EPSper diluted share | -$17.98 | -$16.31 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 9, 2026Form 4 | Khan Bilal ArshadDirector | BuyCommon Stock · indirect | 115.0K | $16.00 | $1.84M | 251.4K |
| Feb 9, 2026Form 4 | Khan Bilal ArshadDirector | BuyCommon Stock | 20.0K | $16.00 | $320.0K | 25.4K |
| Feb 9, 2026Form 4 | Pardo Geoffrey BDirector | BuyCommon Stock · indirect | 312.5K | $16.00 | $5.00M | 2.19M |
| Feb 9, 2026Form 4 | RA Capital Healthcare Fund LP +4Director,TenPercentOwner | BuyCommon Stock · indirect | 248.0K | $16.00 | $3.97M | 2.05M |
| Feb 9, 2026Form 4 | RA Capital Healthcare Fund LP +4Director,TenPercentOwner | BuyCommon Stock · indirect | 3.44M | $16.00 | $55.07M | 5.97M |